Luxembourg, 14/05/2007 (Agence Europe) - The European Investment Bank (EIB) and the Instituto de Credito Oficial (ICO) are jointly providing a €50 million facility to Zeltia Group (EIB: €30 million and ICO €20 million) to support the biopharmaceutical research and development activities of its subsidiary company PharmaMar. These R&D activities are aimed at strengthening the company's priority areas, primarily oncology, through products targeting different forms of cancer.
PharmaMar is...